By Industry Standard Research
In a recent survey focused on clinical development outsourcing, respondents were asked which provider type they would choose if the choice were completely up to them. The longest bar in the adjacent chart stands out — large CROs are overwhelmingly preferred by respondents for conducting Phase 3 trials. Large CROs are also preferred for conducting Phase 4 trials (65% — an uptick of 20 ppts since 2018). Midsized CROs are preferred by respondents for Phase 2 trials (59%). Phase 1 provider preference is fairly mixed.